Monograph
J07BC20 - Combinations |
Propably not porphyrinogenic |
PNP |
Rationale
Based on the pharmacokinetics of the hepatitis combination vaccine, there are no conceivable porphyrinogenic effects.
Chemical description
Inactivated hepatitis A virus and hepatitis B virus surface antigen.
Therapeutic characteristics
The hepatitis combination vaccine is indicated for use in non-immune adults and children from the age of 1 year and above who are at risk of both hepatitis A and hepatitis B infection. It is administered by intramuscular injections according to a three or four dose schedule.
Metabolism and pharmacokinetics
The hepatitis vaccine is not metabolized by the cytochrome P450 system.
IPNet drug reports
Uneventful use reported in 3 patients with acute porphyria.
Similar drugs
References
| # | Citation details | PMID |
|---|---|---|
| * | Government bodies | |
| 1. | Norwegian Institute of Public Health. Vaksinasjonsveilederen. www.fhi.no (updated 13.10.2015).
|
|
| * | Summary of Product Characteristics | |
| 2. | The electronic Medicines Compendium (emc). Summary of Product Characteristics (SPC). Twinrix. (Last edition: January 2015).
|
|
Tradenames
This list comprises raw data collected from different countries.
In some cases, a more comprehensive list of available drug packages is included.
Consequently, very similar terms may therefore appear multiple times.
Bold names are the searchable terms, while the gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Ambirix · Twinrix 
Ambirix · Twinrix 
Ambirix · Twinrix · Tyavax 
Twinrix 
Ambirix vaccine · Hepatyrix · Twinrix · Twinrix Adult vaccine · Twinrix Paediatric vaccine · ViATIM 
Ambirix · Twinrix 
Twinrix 
Ambirix · Twinrix 
Ambirix · Twinrix · Twinrix Enfant 
Ambirix · Twinrix 
Ambirix · Twinrix 
Ambirix · Twinrix 
Twinrix
© NAPOS 2025